Immuron (IMRN) Struggles After Announcing Trial Results
Immuron Limited (NASDAQ:IMRN) is a biotechnology company that provides a medicine to prevent diarrhea and is also developing similar medicines.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Citadel Investment Group Ken Griffin | 19,562 | $37,363 | 0% |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 18,253 | $34,681 | 0% | |
| 2. | 17,968 | $34,319 | 0% | |
| 3. | 5,939 | $11,343 | 0% | |
| 4. | 1,866 | $3,545 | 0% | |
| 5. | 1,312 | $2,493 | 0% |